- Second abstract with data concluding vibegron does not inhibit CYP2D6, a common drug metabolism pathway, also accepted for podium presentation
IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)–Apr. 29, 2019– Urovant Sciences (Nasdaq: UROV),a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced two vibegron abstracts were accepted for plenary and podium presentations, respectively, at the 2019 American Urological Association Annual Meeting in ChicagoMay 3-6, 2019.
The late-breaker presentation of the vibegron international Phase 3 pivotal trial EMPOWUR by Dr. David Staskin, a principal investigator, is scheduled for the Next Frontier Plenary Session on Sunday, May 5, at 1:10 p.m. CT. A second abstract, with data concluding vibegron does not inhibit a common drug metabolism pathway will be presented by Dr. Matthew Rutman during a podium session on Friday, May 3, at 1:00 p.m. CT.
|International Phase 3, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder. EMPOWUR|
|Next Frontier Plenary Session, Sunday Afternoon|
|Sunday, May 5, 2019 at 1:10 – 1:19 p.m. CT|
|Location: MCP: W375d|
|Presenter: David Staskin, MD, Tufts University School of Medicine, Boston|
|Once-Daily Vibegron, a Novel Oral β3 Agonist Does Not Inhibit CYP2D6, a Common Pathway for Drug Metabolism in Patients on OAB Medications|
|Friday, May 3, 2019 at 1:00 – 1:10 p.m. CT|
|Location: MCP: W179b|
|Presenter: Matthew Rutman, MD, Columbia University College of Physicians and Surgeons, New York|
Presentation abstracts may be found on the AUA website at http://www.aua2019.org/abstracts. Additional information about the presentations remain subject to the AUA embargo policy and will be made available at the time of the presentations.
About Urovant Sciences
Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Urovant’s lead product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist being evaluated for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency; for OAB in men with benign prostatic hyperplasia; and for abdominal pain associated with irritable bowel syndrome. Urovant has licensed global rights, excluding Japan and certain Asian territories, for the development and commercialization of vibegron. Urovant’s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacological therapy. Urovant intends to develop treatments for additional urologic diseases. For more information, please visit www.urovant.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical statements of fact and statements regarding the Company’s intent, belief or expectations and can be identified by words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “strive,” “to be,” “will,” “would,” or the negative or plural of these words or other similar expressions or variations, although not all forward-looking statements contain these identifying words. In this press release, forward-looking statements include, but are not limited to, statements regarding the Company’s plans and strategies for the development and commercialization of innovative therapies, including vibegron, for the treatment of urological conditions.
The Company’s forward-looking statements are based on management’s current expectations and beliefs, and are subject to a number of risks and uncertainties that could lead to actual results differing materially from those projected, forecasted or expected. Although the Company believes that the assumptions underlying these forward-looking statements are reasonable, they are not guarantees and the Company can give no assurance that its expectations will be attained. Factors that could materially affect the Company’s operations and future prospects or which could cause actual results to differ materially from expectations include, but are not limited to the risks and uncertainties listed in the Company’s filings with the United States Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed with the SEC on February 14, 2019, as such risk factors may be amended, supplemented or superseded from time to time by other reports the Company files with the SEC. You should not place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof, and, except as required by law, the Company undertakes no obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190429005026/en/